CD47 and neoplasm: IBI322 selectively binds CD47+PD-L1+ tumor cells, effectively inhibits CD47/SIRPα signaling, and instigates intense phagocytosis of CD47+PD-L1+ tumor cells by macrophages in vitro [61].